GSK Cuts U.S. Sales Reps To Gain Greater Share Of China, India Markets
This article was originally published in PharmAsia News
Executive Summary
The U.K.'s GlaxoSmithKline is using a reduction of 1,000 sales jobs in the United States to enhance its expansion plans in China and India. The company said it would lay off the sales reps by the end of the year. CEO Andrew Witty said the company sees a huge future in emerging markets of the East where partnerships are available for marketing branded drugs. Witty's interest in the China market dates back to 2000-2002 when he served as economic adviser to the governor of a Chinese province. (Click here for more
You may also be interested in...
GSK Forms Joint Venture With Shenzhen Neptunus Interlong Bio-Technique For Flu Vaccine
HONG KONG - GlaxoSmithKline announced Nov. 21 a joint venture with Shenzhen Neptunus Interlong Bio-Technique to develop flu vaccines aimed at strains specific to China, Hong Kong and Macau
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.